SF2535 / SignalRx - LARVOL DELTA

Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic Leukemia. (PubMed, Front Oncol) - "Previously, combination of BRD4 and PI3K inhibition with SF2523 was shown to successfully decrease Myc expression. Interestingly, SF2535 decreased the mean fluorescence intensity (MFI) of integrin α4, α5, α6, and β1 while increasing MFI of CXCR4, indicating that SF2535 may work through inside-out signaling of integrins. Taken together, our data provide a rationale for the clinical evaluation of targeting PI3Kδ/BRD4 in refractory or relapsed B-ALL using SF2535."

IO biomarker • Journal • Preclinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • BCL2 • BRD4 • CASP3 • CASP7 • CXCR4 • ITGA4 • MYC • PARP1 • PIK3CD